Biocon Ltd.
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Nov has averaged the highest return (+7.8%); Oct the lowest (-6.8%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.9%Negative MonthJan 2026: -6.94% | +6.3%Positive MonthFeb 2026: +6.33% | -7.4%Negative MonthMar 2026: -7.42% | -0.4%Neutral MonthApr 2026: -0.36% | +19.7%Positive MonthMay 2026: +19.66% | -2.8%Negative MonthJun 2026: -2.75% | +1.7%Neutral MonthJul 2026: +1.68% | -1.9%*Neutral MonthAug 2026: -1.89% | β | β | β | β |
| 2025 | -0.7%Neutral MonthJan 2025: -0.74% | -16.5%Negative MonthFeb 2025: -16.54% | +12.8%Positive MonthMar 2025: +12.76% | -5.7%Negative MonthApr 2025: -5.72% | +4.3%Positive MonthMay 2025: +4.31% | +6.0%Positive MonthJun 2025: +5.98% | +10.0%Positive MonthJul 2025: +9.98% | -10.9%Negative MonthAug 2025: -10.94% | -2.1%Negative MonthSep 2025: -2.14% | +9.1%Positive MonthOct 2025: +9.14% | +7.0%Positive MonthNov 2025: +7.04% | -1.1%Neutral MonthDec 2025: -1.08% |
| 2024 | +7.5%Positive MonthJan 2024: +7.51% | +3.0%Positive MonthFeb 2024: +2.98% | -4.5%Negative MonthMar 2024: -4.48% | +13.1%Positive MonthApr 2024: +13.06% | +3.6%Positive MonthMay 2024: +3.58% | +13.5%Positive MonthJun 2024: +13.48% | +3.2%Positive MonthJul 2024: +3.23% | -0.8%Neutral MonthAug 2024: -0.84% | +1.0%Neutral MonthSep 2024: +1.04% | -12.9%Negative MonthOct 2024: -12.92% | +15.4%Positive MonthNov 2024: +15.39% | +0.1%Neutral MonthDec 2024: +0.12% |
| 2023 | -10.2%Negative MonthJan 2023: -10.20% | -2.6%Negative MonthFeb 2023: -2.59% | -9.9%Negative MonthMar 2023: -9.89% | +12.8%Positive MonthApr 2023: +12.79% | +5.3%Positive MonthMay 2023: +5.35% | +8.3%Positive MonthJun 2023: +8.30% | -3.3%Negative MonthJul 2023: -3.33% | +1.1%Neutral MonthAug 2023: +1.05% | +4.9%Positive MonthSep 2023: +4.92% | -19.3%Negative MonthOct 2023: -19.29% | +8.6%Positive MonthNov 2023: +8.56% | +4.7%Positive MonthDec 2023: +4.74% |
| 2022 | +0.8%Neutral MonthJan 2022: +0.77% | -5.0%Negative MonthFeb 2022: -5.02% | -4.1%Negative MonthMar 2022: -4.13% | +10.1%Positive MonthApr 2022: +10.13% | -9.3%Negative MonthMay 2022: -9.30% | -7.9%Negative MonthJun 2022: -7.85% | -0.3%Neutral MonthJul 2022: -0.29% | +0.8%Neutral MonthAug 2022: +0.85% | -6.1%Negative MonthSep 2022: -6.07% | -7.4%Negative MonthOct 2022: -7.41% | +5.2%Positive MonthNov 2022: +5.16% | -7.6%Negative MonthDec 2022: -7.56% |
| 2021 | β | β | β | β | β | +4.3%Positive MonthJun 2021: +4.33% | -4.4%Negative MonthJul 2021: -4.41% | -7.2%Negative MonthAug 2021: -7.23% | +1.2%Neutral MonthSep 2021: +1.19% | -3.3%Negative MonthOct 2021: -3.33% | +2.7%Positive MonthNov 2021: +2.72% | +1.2%Neutral MonthDec 2021: +1.19% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.24 K Cr | β | βΉ609.00 Cr | β | β | 5.3% | 5.5% | 411.8% |
| Mar 2024 | βΉ2.13 K Cr | β | βΉ119.00 Cr | β | β | 1.1% | 6.7% | -95.8% |
| Mar 2023 | βΉ1.99 K Cr | β | βΉ2.85 K Cr | β | β | 26.1% | 14.7% | 3211.6% |
| Mar 2022 | βΉ1.74 K Cr | β | βΉ86.00 Cr | β | β | 1.1% | -14.3% | -69.3% |
| Mar 2021 | βΉ2.03 K Cr | β | βΉ280.00 Cr | β | β | 3.5% | 2.0% | -36.5% |
| Mar 2020 | βΉ1.99 K Cr | β | βΉ441.00 Cr | β | β | 5.9% | 11.3% | -10.5% |
| Mar 2019 | βΉ1.79 K Cr | β | βΉ493.00 Cr | β | β | 6.9% | -26.2% | 107.1% |
| Mar 2018 | βΉ2.42 K Cr | β | βΉ238.00 Cr | β | β | 3.5% | -6.5% | -54.1% |
| Mar 2017 | βΉ2.59 K Cr | β | βΉ519.00 Cr | β | β | 7.9% | 12.4% | 40.7% |
| Mar 2016 | βΉ2.30 K Cr | β | βΉ369.00 Cr | β | β | 6.2% | 2.7% | 2.2% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 2,202 | 2,242 | 2,302 | 2,588 | 2,419 | 1,786 | 1,988 | 2,028 | 1,738 | 1,993 | 2,127 | 2,243 | 2,327 |
| Total Expenses | 1,729 | 1,812 | 1,880 | 1,996 | 2,101 | 1,575 | 1,702 | 1,716 | 1,677 | 1,969 | 1,864 | 2,066 | 2,160 |
| EBIT / Operating Profit | 473 | 430 | 422 | 592 | 318 | 210 | 286 | 312 | 61 | 24 | 264 | 177 | 167 |
| OPM % | 21% | 19% | 18% | 23% | 13% | 12% | 14% | 15% | 4% | 1% | 12% | 8% | 7% |
| Other Income | 61 | 127 | 279 | 99 | 125 | 422 | 366 | 150 | 187 | 3,134 | 206 | 848 | 930 |
| Finance Costs | 1 | 1 | 2 | 4 | 1 | 3 | 1 | 0 | 0 | 70 | 199 | 237 | 245 |
| Depreciation & Amortisation | 124 | 128 | 140 | 151 | 136 | 92 | 98 | 104 | 108 | 117 | 121 | 128 | 134 |
| Profit Before Tax | 409 | 428 | 559 | 536 | 306 | 537 | 553 | 359 | 140 | 2,971 | 150 | 661 | 717 |
| Tax % | 21% | 16% | 34% | 3% | 22% | 8% | 20% | 22% | 38% | 4% | 21% | 8% | - |
| Net Profit / PAT | 324 | 361 | 369 | 519 | 238 | 493 | 441 | 280 | 86 | 2,848 | 119 | 609 | 668 |
| EPS (βΉ) | 2.70 | 3.01 | 3.07 | 4.33 | 1.99 | 4.11 | 3.67 | 2.34 | 0.72 | 23.72 | 0.99 | 5.07 | 5.51 |
| Dividend Payout % | 31% | 28% | 27% | 12% | 25% | 12% | 0% | 0% | 70% | 6% | 50% | 10% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Biocon Ltd.this co. | βΉ56.87 K Cr | βΉ2.24 K Cr | 709.00 | 3.14 | 124.09 | 5.5% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
